SG11202106401UA - Estrogen receptor antagonist - Google Patents

Estrogen receptor antagonist

Info

Publication number
SG11202106401UA
SG11202106401UA SG11202106401UA SG11202106401UA SG11202106401UA SG 11202106401U A SG11202106401U A SG 11202106401UA SG 11202106401U A SG11202106401U A SG 11202106401UA SG 11202106401U A SG11202106401U A SG 11202106401UA SG 11202106401U A SG11202106401U A SG 11202106401UA
Authority
SG
Singapore
Prior art keywords
receptor antagonist
estrogen receptor
estrogen
antagonist
receptor
Prior art date
Application number
SG11202106401UA
Inventor
Shuwen Duan
Jianyu Lu
Lihong Hu
Charles Z Ding
Guoping Hu
Jian Li
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Medshine Discovery Inc filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11202106401UA publication Critical patent/SG11202106401UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
SG11202106401UA 2018-12-17 2019-12-17 Estrogen receptor antagonist SG11202106401UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201811545117 2018-12-17
CN201910611070 2019-07-08
CN201910877339 2019-09-17
PCT/CN2019/126046 WO2020125640A1 (en) 2018-12-17 2019-12-17 Estrogen receptor antagonist

Publications (1)

Publication Number Publication Date
SG11202106401UA true SG11202106401UA (en) 2021-07-29

Family

ID=71100660

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106401UA SG11202106401UA (en) 2018-12-17 2019-12-17 Estrogen receptor antagonist

Country Status (12)

Country Link
US (1) US20220033376A1 (en)
EP (1) EP3889133A4 (en)
JP (1) JP2022513942A (en)
KR (1) KR20210105384A (en)
CN (2) CN113166055B (en)
AU (1) AU2019400398A1 (en)
BR (1) BR112021011728A8 (en)
CA (1) CA3122621A1 (en)
MX (1) MX2021007088A (en)
PH (1) PH12021551437A1 (en)
SG (1) SG11202106401UA (en)
WO (1) WO2020125640A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043401A1 (en) 2020-12-30 2024-02-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salt form of tetra-substituted olefin compound, crystal, and preparation method therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JP6154887B2 (en) * 2012-03-20 2017-06-28 セラゴン ファーマシューティカルズ,インク. Estrogen receptor modulators and uses thereof
MD3302471T2 (en) 2015-05-29 2021-12-31 Eisai R&D Man Co Ltd Tetrasubstituted alkene compounds and their use
WO2016196342A1 (en) * 2015-05-29 2016-12-08 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use
EP3434668B1 (en) * 2016-03-25 2020-08-26 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Indolo-substituted-piperidine compounds as estrogen receptor degrading agent
MA46896A (en) * 2016-11-24 2019-10-02 Eisai R&D Man Co Ltd TETRASUBSTITUTED ALCENE COMPOUNDS AND THEIR USE

Also Published As

Publication number Publication date
EP3889133A1 (en) 2021-10-06
AU2019400398A1 (en) 2021-07-15
MX2021007088A (en) 2021-09-08
US20220033376A1 (en) 2022-02-03
CN113166055B (en) 2023-09-08
PH12021551437A1 (en) 2021-12-06
JP2022513942A (en) 2022-02-09
BR112021011728A2 (en) 2021-08-31
KR20210105384A (en) 2021-08-26
WO2020125640A1 (en) 2020-06-25
CA3122621A1 (en) 2020-06-25
BR112021011728A8 (en) 2023-01-31
CN113166055A (en) 2021-07-23
CN117430585A (en) 2024-01-23
EP3889133A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
ZA202003023B (en) Benzothiophene-based selective estrogen receptor downregulators
DK3820873T3 (en) Selective estrogen receptor antagonists
IL286461A (en) Estrogen receptor degrading protacs
DK3820874T3 (en) Selective estrogen receptor antagonists
IL268263B (en) Estrogen receptor modulators
GB201702617D0 (en) Receptor
EP3703694A4 (en) Opioid receptor antagonist prodrugs
IL279960A (en) P2x3 receptor antagonists
GB201911187D0 (en) Receptor
IL280199A (en) Receptor for vista
GB201816639D0 (en) GLP-1 Receptor Antagonist
SG11202106401UA (en) Estrogen receptor antagonist
EP3388423A4 (en) Nk1 receptor antagonist
EP3849567A4 (en) Estrogen receptor targeting antagonists
GB201910526D0 (en) Antagonist
GB201812604D0 (en) Antagonist compounds
GB201816650D0 (en) GLP-1 Receptor antagonists
PL3611373T3 (en) Lightning receptor bracket
GB201817943D0 (en) Galanin-2 receptor agonists
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor